These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23906625)

  • 1. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
    Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
    Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge of the 'C' in CML.
    Mauro MJ
    Leuk Res; 2014 Mar; 38(3):286. PubMed ID: 24439564
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
    Efficace F; Baccarani M; Breccia M; Cottone F; Alimena G; Deliliers GL; Baratè C; Specchia G; Di Lorenzo R; Luciano L; Turri D; Martino B; Stagno F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Fava C; Veneri D; Sica S; Rambaldi A; Rosti G; Vignetti M; Mandelli F
    Leukemia; 2013 Jul; 27(7):1511-9. PubMed ID: 23417029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient empowerment in the management of chronic myeloid leukemia.
    Coleman M
    Clin J Oncol Nurs; 2014 Apr; 18(2):E12-8. PubMed ID: 24675265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cultural factors related to adherence to imatinib in CML: a Mexican perspective.
    Cantú-Rodríguez OG; Sánchez-Cárdenas M; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Mancias-Guerra C; González-Llano O; Gómez-Almaguer D
    Hematology; 2015 Mar; 20(2):72-6. PubMed ID: 25034734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
    Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
    Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
    Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
    Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
    Eliasson L; Clifford S; Barber N; Marin D
    Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
    Imataki O
    Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
    [No Abstract]   [Full Text] [Related]  

  • 13. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
    Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
    Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
    Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
    J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors.
    Coetzee MJ; Louw VJ; Gartrell K; Viljoen CD
    S Afr Med J; 2009 Dec; 99(12):870-1. PubMed ID: 20459996
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
    Mustjoki S; Richter J; Barbany G; Ehrencrona H; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Hernesniemi S; Josefsen D; Koskenvesa P; Dybedal I; Markevärn B; Olofsson T; Olsson-Strömberg U; Rapakko K; Thunberg S; Stenke L; Simonsson B; Porkka K; Hjorth-Hansen H;
    Leukemia; 2013 Jul; 27(7):1520-6. PubMed ID: 23328954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.